PNC-27

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Use in healthy subjects without confirmed malignancy: PNC-27's therapeutic window is predicated on cancer cell membrane HDM-2 overexpression; in non-malignant subjects the selectivity basis is absent and normal cells under stress may express sufficient membrane HDM-2 to be vulnerable to PNC-27-mediated membrane disruption.
• Active organ transplant with functioning allograft: necrotic cell death from PNC-27 releases DAMPs that activate innate immune pattern recognition; in immunosuppressed transplant recipients, this immune activation could be poorly managed and may trigger rejection episodes.
• Severe autoimmune disease: the inflammatory response from tumor cell necrosis and DAMP release could trigger or worsen autoimmune flares.
• Severe hepatic impairment: clearance of necrotic cellular debris and peptide metabolism are hepatically dependent; impaired hepatic function may lead to toxic accumulation of necrotic byproducts.
• Known hypersensitivity to PNC-27, penetratin-derived sequences, p53-derived peptides, or formulation excipients.
• Concurrent use with active chemotherapy regimens without oncological coordination: PNC-27's necrotic cell death mechanism could interact unpredictably with chemotherapy-induced apoptotic cell death kinetics and immune responses.
• Pregnancy: the membrane-disrupting mechanism and necrosis induction have no established safety profile during pregnancy; absolute contraindication.
• Pediatric use: no safety or dosing data in pediatric subjects.
• Subjects with significant tumor burden in proximity to critical structures: rapid necrotic cell death of large tumor volumes adjacent to critical vasculature, nerves, or organs could produce local acute inflammatory or hemorrhagic events.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Fatigue: the most commonly reported adverse effect during PNC-27 use; driven by the systemic metabolic and immune demand of processing necrotic tumor cell debris; correlates with tumor burden and killing rate.
• Flu-like immune response during cell necrosis: necrotic cancer cell death releases intracellular DAMPs, heat shock proteins, and tumor antigens that activate pattern recognition receptors (TLR-2, TLR-4, NLRP3 inflammasome) on innate immune cells; produces systemic inflammation characterized by low-grade fever, malaise, myalgia, and fatigue resembling influenza; the intensity correlates with the rate and volume of tumor cell necrosis.
• Injection site local inflammation: subcutaneous PNC-27 injection can produce local tissue reaction; the membrane-disrupting properties of the penetratin sequence may cause local non-specific tissue irritation beyond standard peptide injection reactions.
• Tumor lysis-like inflammatory events: at higher doses or with rapidly responding tumors, the sudden release of intracellular contents from mass tumor cell necrosis could produce metabolic disturbances (elevated uric acid, potassium, phosphate) analogous to tumor lysis syndrome seen with cytotoxic chemotherapy; requires metabolic monitoring at higher doses.
• Nausea: related to the systemic inflammatory response from necrotic debris processing.
• Headache: from systemic DAMP-driven cytokine release during active tumor necrosis.
• Localized pain at tumor sites: necrotic destruction of tumor tissue with associated inflammatory response; may manifest as pain, swelling, or warmth at known tumor locations during active treatment.
• Unknown off-target membrane disruption risk in stressed normal cells: theoretical; depends on degree of stress-induced surface HDM-2 expression in non-malignant tissue; the full off-target safety profile in humans is not established.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• PubMed search: PNC-27